Jamunarani Veeraraghavan, Ph.D. - Publications

2012 University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States 
Pathology, Oncology, Biochemistry

12/31 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Kim JA, Tan Y, Wang X, Cao X, Veeraraghavan J, Liang Y, Edwards DP, Huang S, Pan X, Li K, Schiff R, Wang XS. Comprehensive functional analysis of the tousled-like kinase 2 frequently amplified in aggressive luminal breast cancers. Nature Communications. 7: 12991. PMID 27694828 DOI: 10.1038/ncomms12991  0.52
2016 Veeraraghavan J, Ma J, Hu Y, Wang XS. Recurrent and pathological gene fusions in breast cancer: current advances in genomic discovery and clinical implications. Breast Cancer Research and Treatment. PMID 27372070 DOI: 10.1007/s10549-016-3876-y  0.52
2013 Aravindan S, Natarajan M, Veeraraghavan J, Herman TS, Aravindan N. Inflammatory signature after low dose γ-radiation in mice brain and gut: Switch from therapeutic benefit to inflammation European Journal of Inflammation. 11: 405-418.  0.52
2011 Aravindan N, Thomas CR, Aravindan S, Mohan AS, Veeraraghavan J, Natarajan M. Irreversible EGFR inhibitor EKB-569 targets low-LET γ-radiation-triggered rel orchestration and potentiates cell death in squamous cell carcinoma. Plos One. 6: e29705. PMID 22242139 DOI: 10.1371/journal.pone.0029705  0.52
2011 Veeraraghavan J, Natarajan M, Lagisetty P, Awasthi V, Herman TS, Aravindan N. Impact of curcumin, raspberry extract, and neem leaf extract on rel protein-regulated cell death/radiosensitization in pancreatic cancer cells. Pancreas. 40: 1107-19. PMID 21697760 DOI: 10.1097/MPA.0b013e31821f677d  0.52
2011 Veeraraghavan J, Natarajan M, Aravindan S, Herman TS, Aravindan N. Radiation-triggered tumor necrosis factor (TNF) alpha-NFkappaB cross-signaling favors survival advantage in human neuroblastoma cells. The Journal of Biological Chemistry. 286: 21588-600. PMID 21527635 DOI: 10.1074/jbc.M110.193755  0.52
2011 Veeraraghavan J, Aravindan S, Natarajan M, Awasthi V, Herman TS, Aravindan N. Neem leaf extract induces radiosensitization in human neuroblastoma xenograft through modulation of apoptotic pathway. Anticancer Research. 31: 161-70. PMID 21273594  0.52
2011 Aravindan N, Veeraraghavan J, Madhusoodhanan R, Herman TS, Natarajan M. Curcumin regulates low-linear energy transfer γ-radiation-induced NFκB-dependent telomerase activity in human neuroblastoma cells. International Journal of Radiation Oncology, Biology, Physics. 79: 1206-15. PMID 21236599 DOI: 10.1016/j.ijrobp.2010.10.058  0.52
2011 Veeraraghavan J, Natarajan M, Herman TS, Aravindan N. Low-dose γ-radiation-induced oxidative stress response in mouse brain and gut: regulation by NFκB-MnSOD cross-signaling. Mutation Research. 718: 44-55. PMID 21056117 DOI: 10.1016/j.mrgentox.2010.10.006  0.52
2010 Veeraraghavan J, Natarajan M, Herman TS, Aravindan N. Curcumin-altered p53-response genes regulate radiosensitivity in p53-mutant Ewing's sarcoma cells. Anticancer Research. 30: 4007-15. PMID 21036715  0.52
2009 Madhusoodhanan R, Natarajan M, Veeraraghavan J, Herman TS, Jamgade A, Singh N, Aravindan N. NFkappaB signaling related molecular alterations in human neuroblastoma cells after fractionated irradiation. Journal of Radiation Research. 50: 311-24. PMID 19436149 DOI: JST.JSTAGE/jrr/08110  0.52
2009 Madhusoodhanan R, Natarajan M, Veeraraghavan J, Herman TS, Aravindan N. NFkappaB activity and transcriptional responses in human breast adenocarcinoma cells after single and fractionated irradiation. Cancer Biology & Therapy. 8: 765-73. PMID 19276662  0.52
Low-probability matches
2019 Rimawi MF, Niravath P, Wang T, Rexer BN, Forero A, Wolff AC, Nanda R, Storniolo AM, Krop I, Goetz MP, Nangia JR, Jiralerspong S, Pavlick A, Veeraraghavan J, De Angelis C, et al. TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 vs. 24 Weeks in Patients with HER2-positive Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31662331 DOI: 10.1158/1078-0432.CCR-19-0851  0.01
2019 De Angelis C, Nagi C, Hoyt CC, Liu L, Roman K, Wang C, Zheng Y, Veeraraghavan J, Sethunath V, Nuciforo P, Wang T, Tsimelzon A, Mao S, Hilsenbeck SG, Trivedi MV, et al. Evaluation of the predictive role of tumor immune infiltrate in HER2-positive breast cancer patients treated with neoadjuvant anti-HER2 therapy without chemotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31653641 DOI: 10.1158/1078-0432.CCR-19-1402  0.01
2019 Sethunath V, Hu H, De Angelis C, Veeraraghavan J, Qin L, Wang N, Simon LM, Wang T, Fu X, Nardone A, Pereira R, Nanda S, Griffith OL, Tsimelzon A, Shaw C, et al. . Molecular Cancer Research : McR. PMID 31420371 DOI: 10.1158/1541-7786.MCR-19-0756  0.01
2019 Prat A, Pascual T, De Angelis C, Gutierrez C, Llombart-Cussac A, Wang T, Cortés J, Rexer B, Paré L, Forero A, Wolff AC, Morales S, Adamo B, Brasó-Maristany F, Vidal M, ... Veeraraghavan J, et al. HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade. Journal of the National Cancer Institute. PMID 31037288 DOI: 10.1093/jnci/djz042  0.01
2018 Nardone A, Weir H, Delpuech O, Brown H, De Angelis C, Cataldo ML, Fu X, Shea MJ, Mitchell T, Veeraraghavan J, Nagi C, Pilling M, Rimawi MF, Trivedi M, Hilsenbeck SG, et al. The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance. British Journal of Cancer. PMID 30555156 DOI: 10.1038/s41416-018-0354-9  0.01
2017 Veeraraghavan J, De Angelis C, Reis-Filho JS, Pascual T, Prat A, Rimawi MF, Osborne CK, Schiff R. De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance. Breast (Edinburgh, Scotland). PMID 28687441 DOI: 10.1016/j.breast.2017.06.022  0.01
2017 Xu X, De Angelis C, Burke KA, Nardone A, Hu H, Qin L, Veeraraghavan J, Sethunath V, Heiser LM, Wang NJ, Ng CKY, Chen E, Renwick A, Wang T, Nanda S, et al. HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28487443 DOI: 10.1158/1078-0432.CCR-16-2191  0.01
2016 Wang X, Kim JA, Anurag M, Veeraraghavan J, Schiff R, Li K. Amplification of TLK2 Induces Genomic Instability via Impairing the G2/M Checkpoint. Molecular Cancer Research : McR. PMID 27489360 DOI: 10.1158/1541-7786.MCR-16-0161  0.01
2015 Southwell AL, Franciosi S, Villanueva EB, Xie Y, Winter LA, Veeraraghavan J, Jonason A, Felczak B, Zhang W, Kovalik V, Waltl S, Hall G, Pouladi MA, Smith ES, Bowers WJ, et al. Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease. Neurobiology of Disease. 76: 46-56. PMID 25662335 DOI: 10.1016/j.nbd.2015.01.002  0.01
2015 Evans EE, Jonason AS, Bussler H, Torno S, Veeraraghavan J, Reilly C, Doherty MA, Seils J, Winter LA, Mallow C, Kirk R, Howell A, Giralico S, Scrivens M, Klimatcheva K, et al. Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies. Cancer Immunology Research. 3: 689-701. PMID 25614511 DOI: 10.1158/2326-6066.CIR-14-0171  0.01
2014 Smith ES, Jonason A, Reilly C, Veeraraghavan J, Fisher T, Doherty M, Klimatcheva E, Mallow C, Cornelius C, Leonard JE, Marchi N, Janigro D, Argaw AT, Pham T, Seils J, et al. SEMA4D compromises blood-brain barrier, activates microglia, and inhibits remyelination in neurodegenerative disease. Neurobiology of Disease. 73: 254-268. PMID 25461192 DOI: 10.1016/j.nbd.2014.10.008  0.01
2014 Veeraraghavan J, Tan Y, Cao XX, Kim JA, Wang X, Chamness GC, Maiti SN, Cooper LJ, Edwards DP, Contreras A, Hilsenbeck SG, Chang EC, Schiff R, Wang XS. Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers. Nature Communications. 5: 4577. PMID 25099679 DOI: 10.1038/ncomms5577  0.01
2004 Liu Y, Zhang H, Veeraraghavan J, Bambara RA, Freudenreich CH. Saccharomyces cerevisiae flap endonuclease 1 uses flap equilibration to maintain triplet repeat stability. Molecular and Cellular Biology. 24: 4049-64. PMID 15082797 DOI: 10.1128/MCB.24.9.4049-4064.2004  0.01
2004 Kao HI, Veeraraghavan J, Polaczek P, Campbell JL, Bambara RA. On the roles of Saccharomyces cerevisiae Dna2p and Flap endonuclease 1 in Okazaki fragment processing. The Journal of Biological Chemistry. 279: 15014-24. PMID 14747468 DOI: 10.1074/jbc.M313216200  0.01
2003 Veeraraghavan J, Rossi ML, Bambara RA. Analysis of DNA replication intermediates suggests mechanisms of repeat sequence expansion. The Journal of Biological Chemistry. 278: 42854-66. PMID 12902352 DOI: 10.1074/jbc.M305137200  0.01
2002 Henricksen LA, Veeraraghavan J, Chafin DR, Bambara RA. DNA ligase I competes with FEN1 to expand repetitive DNA sequences in vitro. The Journal of Biological Chemistry. 277: 22361-9. PMID 11948189 DOI: 10.1074/jbc.M201765200  0.01
1975 Veeraraghavan J. Stability in Pyricularia oryzae Cav Proceedings of the Indian Academy of Sciences - Section B. 82: 127-131. DOI: 10.1007/BF03050525  0.01
1967 Padmanabhan SY, Chakrabarti NK, Mathur SC, Veeraraghavan J. Physiologic specialisation in Piricularia Oryzae Cav Proceedings of the Indian Academy of Sciences - Section B. 66: 63-73. DOI: 10.1007/BF03051671  0.01
1965 Veeraraghavan J, Padmanabhan SY. Studies on the host range of Piricularia oryzae Cav. causing blast disease of rice Proceedings of the Indian Academy of Sciences - Section B. 61: 109-120. DOI: 10.1007/BF03052091  0.01
Hide low-probability matches.